Live
- Minister Nara Lokesh Pays Emotional Tribute to Late Nara Rammurthy Naidu
- Bihar: Deceased patient's eye missing, RJD condemns incident at Nalanda Medical College
- Rammurthy Naidu's Last Rites Held in Naravari Palli
- PM Modi receives ceremonial welcome in Abuja, begins bilateral talks with Nigerian President Tinubu
- Goods traffic doubles on the new railway freight corridors
- BGT 2024-25: I’d like to see him make one more Test ton in Australia, says Johnso
- Harassment due to ED raids forced Kailash Gehlot to quit, hints Kejriwal
- Kailash Gehlot exit: BJP goes on the offensive against 'corrupt' AAP govt
- PM Modi pays homage to ‘the great’ Balasaheb Thackeray on his death anniversary
- One who cares for Delhi will not stay with gang of robbers: Sachdeva on Gahlot's resignation
Biological E & CEPI partner for COVAX
Biological E & CEPI partner for COVAX
CEPI and Bio E are committed to global equitable access of Covid-19 vaccines and have agreed that vaccine output funded by CEPI investment will be made available for procurement and allocation, if proven to be safe and effective, through the Covid-19 Vaccine Global Access (COVAX) facility
Hyderabad: Norway-headquartered Coalition for Epidemic Preparedness Innovations (CEPI) and City- based Biological E Limited on Tuesday announced a collaboration to advance the development and manufacture of the latter's Covid-19 subunit vaccine candidate.
CEPI will initially contribute up to $ 5 million towards the cost of scaling up the process for manufacturing the vaccine and will explore providing additional funding with a goal of potentially enabling the production of 100 million doses in 2021, Bio E said in a press release here.
Bio E initiated phase 1/2 clinical trial in the country last month to evaluate the safety and immunogenicity of the vaccine candidate and expects interim data from the trial to be available in the first quarter of 2021.
CEPI and Bio E are committed to global equitable access of Covid-19 vaccines and have agreed that vaccine output funded by CEPI investment will be made available for procurement and allocation, if proven to be safe and effective, through the Covid-19 Vaccine Global Access (COVAX) Facility, the release said. The COVAX facility aims to ensure equitable access to Covid-19 vaccines for all countries, at all levels of development, that wish to participate.
CEPI Chief Executive Officer Richard Hatchett said Bio Es vaccine candidate has the potential to be produced at scale, and characteristics which could make it suitable for broad distribution in developing countries. I'm pleased to partner with Bio E to progress the development of this promising vaccine."
Biological E Managing Director Mahima Datla said "This collaboration with CEPI validates the technology platform Bio E is working on for developing an effective Covid-19 vaccine candidate.
"The initial investment from CEPI comes on the heels of investments from the Bill & Melinda Gates Foundation and the Government of India's Biotechnology Industry Research Assistance Council (BIRAC), and provides the impetus for accelerated efforts towards a successful and scalable outcome for global access, she added.
